nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—HTR2C—Sorafenib—kidney cancer	0.0692	0.139	CbGbCtD
Escitalopram—CYP2D6—Temsirolimus—kidney cancer	0.068	0.137	CbGbCtD
Escitalopram—CYP3A4—Everolimus—kidney cancer	0.064	0.129	CbGbCtD
Escitalopram—CYP3A4—Temsirolimus—kidney cancer	0.0433	0.0868	CbGbCtD
Escitalopram—CYP2D6—Pazopanib—kidney cancer	0.0357	0.0717	CbGbCtD
Escitalopram—CYP2C19—Sorafenib—kidney cancer	0.0273	0.0547	CbGbCtD
Escitalopram—CYP2D6—Erlotinib—kidney cancer	0.0255	0.0512	CbGbCtD
Escitalopram—CYP3A4—Pazopanib—kidney cancer	0.0227	0.0456	CbGbCtD
Escitalopram—CYP2D6—Sorafenib—kidney cancer	0.0207	0.0416	CbGbCtD
Escitalopram—CYP2D6—Vinblastine—kidney cancer	0.0205	0.0411	CbGbCtD
Escitalopram—CYP3A4—Erlotinib—kidney cancer	0.0162	0.0325	CbGbCtD
Escitalopram—CYP3A4—Paclitaxel—kidney cancer	0.0148	0.0298	CbGbCtD
Escitalopram—CYP3A4—Sorafenib—kidney cancer	0.0132	0.0265	CbGbCtD
Escitalopram—CYP3A4—Vinblastine—kidney cancer	0.013	0.0261	CbGbCtD
Escitalopram—CYP3A4—Vincristine—kidney cancer	0.0128	0.0257	CbGbCtD
Escitalopram—CYP2D6—Doxorubicin—kidney cancer	0.0126	0.0252	CbGbCtD
Escitalopram—CYP3A4—Sunitinib—kidney cancer	0.0107	0.0214	CbGbCtD
Escitalopram—CYP3A4—Doxorubicin—kidney cancer	0.008	0.0161	CbGbCtD
Escitalopram—Citalopram—ABCB1—kidney cancer	0.00154	1	CrCbGaD
Escitalopram—Nervous system disorder—Paclitaxel—kidney cancer	6.86e-05	0.000149	CcSEcCtD
Escitalopram—Hypokalaemia—Doxorubicin—kidney cancer	6.85e-05	0.000148	CcSEcCtD
Escitalopram—Thrombocytopenia—Paclitaxel—kidney cancer	6.85e-05	0.000148	CcSEcCtD
Escitalopram—Tachycardia—Paclitaxel—kidney cancer	6.83e-05	0.000148	CcSEcCtD
Escitalopram—Rash—Sorafenib—kidney cancer	6.82e-05	0.000148	CcSEcCtD
Escitalopram—Dermatitis—Sorafenib—kidney cancer	6.82e-05	0.000148	CcSEcCtD
Escitalopram—Back pain—Capecitabine—kidney cancer	6.8e-05	0.000147	CcSEcCtD
Escitalopram—Breast disorder—Doxorubicin—kidney cancer	6.8e-05	0.000147	CcSEcCtD
Escitalopram—Skin disorder—Paclitaxel—kidney cancer	6.79e-05	0.000147	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	6.78e-05	0.000147	CcSEcCtD
Escitalopram—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	6.78e-05	0.000147	CcSEcCtD
Escitalopram—Headache—Sorafenib—kidney cancer	6.78e-05	0.000147	CcSEcCtD
Escitalopram—Muscle spasms—Capecitabine—kidney cancer	6.76e-05	0.000146	CcSEcCtD
Escitalopram—Hyperhidrosis—Paclitaxel—kidney cancer	6.76e-05	0.000146	CcSEcCtD
Escitalopram—Diarrhoea—Dactinomycin—kidney cancer	6.74e-05	0.000146	CcSEcCtD
Escitalopram—Nasopharyngitis—Doxorubicin—kidney cancer	6.73e-05	0.000146	CcSEcCtD
Escitalopram—Anorexia—Paclitaxel—kidney cancer	6.67e-05	0.000144	CcSEcCtD
Escitalopram—Gastritis—Doxorubicin—kidney cancer	6.66e-05	0.000144	CcSEcCtD
Escitalopram—Muscular weakness—Doxorubicin—kidney cancer	6.64e-05	0.000144	CcSEcCtD
Escitalopram—Alanine aminotransferase increased—Doxorubicin—kidney cancer	6.64e-05	0.000144	CcSEcCtD
Escitalopram—Vision blurred—Capecitabine—kidney cancer	6.63e-05	0.000144	CcSEcCtD
Escitalopram—Vomiting—Sunitinib—kidney cancer	6.62e-05	0.000143	CcSEcCtD
Escitalopram—Body temperature increased—Gemcitabine—kidney cancer	6.6e-05	0.000143	CcSEcCtD
Escitalopram—Tremor—Capecitabine—kidney cancer	6.59e-05	0.000143	CcSEcCtD
Escitalopram—Rash—Sunitinib—kidney cancer	6.56e-05	0.000142	CcSEcCtD
Escitalopram—Dermatitis—Sunitinib—kidney cancer	6.56e-05	0.000142	CcSEcCtD
Escitalopram—Abdominal distension—Doxorubicin—kidney cancer	6.55e-05	0.000142	CcSEcCtD
Escitalopram—Hypotension—Paclitaxel—kidney cancer	6.54e-05	0.000142	CcSEcCtD
Escitalopram—Ill-defined disorder—Capecitabine—kidney cancer	6.52e-05	0.000141	CcSEcCtD
Escitalopram—Headache—Sunitinib—kidney cancer	6.52e-05	0.000141	CcSEcCtD
Escitalopram—Asthma—Doxorubicin—kidney cancer	6.51e-05	0.000141	CcSEcCtD
Escitalopram—Influenza—Doxorubicin—kidney cancer	6.51e-05	0.000141	CcSEcCtD
Escitalopram—Dysphagia—Doxorubicin—kidney cancer	6.51e-05	0.000141	CcSEcCtD
Escitalopram—Anaemia—Capecitabine—kidney cancer	6.5e-05	0.000141	CcSEcCtD
Escitalopram—Hypersensitivity—Vincristine—kidney cancer	6.49e-05	0.00014	CcSEcCtD
Escitalopram—Eosinophilia—Doxorubicin—kidney cancer	6.44e-05	0.000139	CcSEcCtD
Escitalopram—Nausea—Sorafenib—kidney cancer	6.43e-05	0.000139	CcSEcCtD
Escitalopram—Pancreatitis—Doxorubicin—kidney cancer	6.38e-05	0.000138	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Paclitaxel—kidney cancer	6.37e-05	0.000138	CcSEcCtD
Escitalopram—Malaise—Capecitabine—kidney cancer	6.34e-05	0.000137	CcSEcCtD
Escitalopram—Angina pectoris—Doxorubicin—kidney cancer	6.34e-05	0.000137	CcSEcCtD
Escitalopram—Insomnia—Paclitaxel—kidney cancer	6.33e-05	0.000137	CcSEcCtD
Escitalopram—Vertigo—Capecitabine—kidney cancer	6.32e-05	0.000137	CcSEcCtD
Escitalopram—Asthenia—Vincristine—kidney cancer	6.32e-05	0.000137	CcSEcCtD
Escitalopram—Syncope—Capecitabine—kidney cancer	6.31e-05	0.000137	CcSEcCtD
Escitalopram—Leukopenia—Capecitabine—kidney cancer	6.29e-05	0.000136	CcSEcCtD
Escitalopram—Paraesthesia—Paclitaxel—kidney cancer	6.28e-05	0.000136	CcSEcCtD
Escitalopram—Vomiting—Dactinomycin—kidney cancer	6.27e-05	0.000136	CcSEcCtD
Escitalopram—Bronchitis—Doxorubicin—kidney cancer	6.26e-05	0.000135	CcSEcCtD
Escitalopram—Dyspnoea—Paclitaxel—kidney cancer	6.24e-05	0.000135	CcSEcCtD
Escitalopram—Somnolence—Paclitaxel—kidney cancer	6.22e-05	0.000135	CcSEcCtD
Escitalopram—Palpitations—Capecitabine—kidney cancer	6.21e-05	0.000135	CcSEcCtD
Escitalopram—Rash—Dactinomycin—kidney cancer	6.21e-05	0.000135	CcSEcCtD
Escitalopram—Nausea—Sunitinib—kidney cancer	6.18e-05	0.000134	CcSEcCtD
Escitalopram—Loss of consciousness—Capecitabine—kidney cancer	6.18e-05	0.000134	CcSEcCtD
Escitalopram—Pancytopenia—Doxorubicin—kidney cancer	6.18e-05	0.000134	CcSEcCtD
Escitalopram—Dyspepsia—Paclitaxel—kidney cancer	6.16e-05	0.000133	CcSEcCtD
Escitalopram—Cough—Capecitabine—kidney cancer	6.14e-05	0.000133	CcSEcCtD
Escitalopram—Dysuria—Doxorubicin—kidney cancer	6.08e-05	0.000132	CcSEcCtD
Escitalopram—Decreased appetite—Paclitaxel—kidney cancer	6.08e-05	0.000132	CcSEcCtD
Escitalopram—Hypertension—Capecitabine—kidney cancer	6.07e-05	0.000131	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.05e-05	0.000131	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.04e-05	0.000131	CcSEcCtD
Escitalopram—Fatigue—Paclitaxel—kidney cancer	6.03e-05	0.000131	CcSEcCtD
Escitalopram—Diarrhoea—Vincristine—kidney cancer	6.02e-05	0.00013	CcSEcCtD
Escitalopram—Pollakiuria—Doxorubicin—kidney cancer	6.01e-05	0.00013	CcSEcCtD
Escitalopram—Asthenia—Gemcitabine—kidney cancer	5.99e-05	0.00013	CcSEcCtD
Escitalopram—Chest pain—Capecitabine—kidney cancer	5.99e-05	0.00013	CcSEcCtD
Escitalopram—Arthralgia—Capecitabine—kidney cancer	5.99e-05	0.00013	CcSEcCtD
Escitalopram—Myalgia—Capecitabine—kidney cancer	5.99e-05	0.00013	CcSEcCtD
Escitalopram—Pain—Paclitaxel—kidney cancer	5.98e-05	0.00013	CcSEcCtD
Escitalopram—Constipation—Paclitaxel—kidney cancer	5.98e-05	0.00013	CcSEcCtD
Escitalopram—Anxiety—Capecitabine—kidney cancer	5.97e-05	0.000129	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	5.95e-05	0.000129	CcSEcCtD
Escitalopram—Photosensitivity reaction—Doxorubicin—kidney cancer	5.94e-05	0.000129	CcSEcCtD
Escitalopram—Weight increased—Doxorubicin—kidney cancer	5.92e-05	0.000128	CcSEcCtD
Escitalopram—Discomfort—Capecitabine—kidney cancer	5.92e-05	0.000128	CcSEcCtD
Escitalopram—Pruritus—Gemcitabine—kidney cancer	5.91e-05	0.000128	CcSEcCtD
Escitalopram—Weight decreased—Doxorubicin—kidney cancer	5.89e-05	0.000127	CcSEcCtD
Escitalopram—Hyperglycaemia—Doxorubicin—kidney cancer	5.87e-05	0.000127	CcSEcCtD
Escitalopram—Dry mouth—Capecitabine—kidney cancer	5.86e-05	0.000127	CcSEcCtD
Escitalopram—Nausea—Dactinomycin—kidney cancer	5.85e-05	0.000127	CcSEcCtD
Escitalopram—Pneumonia—Doxorubicin—kidney cancer	5.83e-05	0.000126	CcSEcCtD
Escitalopram—Dizziness—Vincristine—kidney cancer	5.82e-05	0.000126	CcSEcCtD
Escitalopram—Infestation NOS—Doxorubicin—kidney cancer	5.8e-05	0.000126	CcSEcCtD
Escitalopram—Infestation—Doxorubicin—kidney cancer	5.8e-05	0.000126	CcSEcCtD
Escitalopram—Confusional state—Capecitabine—kidney cancer	5.79e-05	0.000125	CcSEcCtD
Escitalopram—Feeling abnormal—Paclitaxel—kidney cancer	5.76e-05	0.000125	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	5.75e-05	0.000125	CcSEcCtD
Escitalopram—Oedema—Capecitabine—kidney cancer	5.74e-05	0.000124	CcSEcCtD
Escitalopram—Gastrointestinal pain—Paclitaxel—kidney cancer	5.72e-05	0.000124	CcSEcCtD
Escitalopram—Diarrhoea—Gemcitabine—kidney cancer	5.72e-05	0.000124	CcSEcCtD
Escitalopram—Infection—Capecitabine—kidney cancer	5.7e-05	0.000123	CcSEcCtD
Escitalopram—Neuropathy peripheral—Doxorubicin—kidney cancer	5.69e-05	0.000123	CcSEcCtD
Escitalopram—Jaundice—Doxorubicin—kidney cancer	5.65e-05	0.000122	CcSEcCtD
Escitalopram—Stomatitis—Doxorubicin—kidney cancer	5.65e-05	0.000122	CcSEcCtD
Escitalopram—Shock—Capecitabine—kidney cancer	5.65e-05	0.000122	CcSEcCtD
Escitalopram—Conjunctivitis—Doxorubicin—kidney cancer	5.64e-05	0.000122	CcSEcCtD
Escitalopram—Urinary tract infection—Doxorubicin—kidney cancer	5.64e-05	0.000122	CcSEcCtD
Escitalopram—Nervous system disorder—Capecitabine—kidney cancer	5.63e-05	0.000122	CcSEcCtD
Escitalopram—Thrombocytopenia—Capecitabine—kidney cancer	5.62e-05	0.000122	CcSEcCtD
Escitalopram—Tachycardia—Capecitabine—kidney cancer	5.6e-05	0.000121	CcSEcCtD
Escitalopram—Vomiting—Vincristine—kidney cancer	5.6e-05	0.000121	CcSEcCtD
Escitalopram—Skin disorder—Capecitabine—kidney cancer	5.57e-05	0.000121	CcSEcCtD
Escitalopram—Sweating—Doxorubicin—kidney cancer	5.56e-05	0.00012	CcSEcCtD
Escitalopram—Urticaria—Paclitaxel—kidney cancer	5.56e-05	0.00012	CcSEcCtD
Escitalopram—Rash—Vincristine—kidney cancer	5.55e-05	0.00012	CcSEcCtD
Escitalopram—Hyperhidrosis—Capecitabine—kidney cancer	5.55e-05	0.00012	CcSEcCtD
Escitalopram—Dermatitis—Vincristine—kidney cancer	5.55e-05	0.00012	CcSEcCtD
Escitalopram—Haematuria—Doxorubicin—kidney cancer	5.53e-05	0.00012	CcSEcCtD
Escitalopram—Body temperature increased—Paclitaxel—kidney cancer	5.53e-05	0.00012	CcSEcCtD
Escitalopram—Abdominal pain—Paclitaxel—kidney cancer	5.53e-05	0.00012	CcSEcCtD
Escitalopram—Headache—Vincristine—kidney cancer	5.52e-05	0.000119	CcSEcCtD
Escitalopram—Hepatobiliary disease—Doxorubicin—kidney cancer	5.49e-05	0.000119	CcSEcCtD
Escitalopram—Epistaxis—Doxorubicin—kidney cancer	5.47e-05	0.000118	CcSEcCtD
Escitalopram—Anorexia—Capecitabine—kidney cancer	5.47e-05	0.000118	CcSEcCtD
Escitalopram—Sinusitis—Doxorubicin—kidney cancer	5.44e-05	0.000118	CcSEcCtD
Escitalopram—Agranulocytosis—Doxorubicin—kidney cancer	5.41e-05	0.000117	CcSEcCtD
Escitalopram—Hypotension—Capecitabine—kidney cancer	5.36e-05	0.000116	CcSEcCtD
Escitalopram—Vomiting—Gemcitabine—kidney cancer	5.31e-05	0.000115	CcSEcCtD
Escitalopram—Bradycardia—Doxorubicin—kidney cancer	5.3e-05	0.000115	CcSEcCtD
Escitalopram—Rash—Gemcitabine—kidney cancer	5.27e-05	0.000114	CcSEcCtD
Escitalopram—Dermatitis—Gemcitabine—kidney cancer	5.26e-05	0.000114	CcSEcCtD
Escitalopram—Haemoglobin—Doxorubicin—kidney cancer	5.23e-05	0.000113	CcSEcCtD
Escitalopram—Headache—Gemcitabine—kidney cancer	5.23e-05	0.000113	CcSEcCtD
Escitalopram—Nausea—Vincristine—kidney cancer	5.23e-05	0.000113	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.23e-05	0.000113	CcSEcCtD
Escitalopram—Rhinitis—Doxorubicin—kidney cancer	5.22e-05	0.000113	CcSEcCtD
Escitalopram—Haemorrhage—Doxorubicin—kidney cancer	5.21e-05	0.000113	CcSEcCtD
Escitalopram—Hepatitis—Doxorubicin—kidney cancer	5.21e-05	0.000113	CcSEcCtD
Escitalopram—Insomnia—Capecitabine—kidney cancer	5.19e-05	0.000112	CcSEcCtD
Escitalopram—Hypoaesthesia—Doxorubicin—kidney cancer	5.18e-05	0.000112	CcSEcCtD
Escitalopram—Pharyngitis—Doxorubicin—kidney cancer	5.17e-05	0.000112	CcSEcCtD
Escitalopram—Paraesthesia—Capecitabine—kidney cancer	5.15e-05	0.000112	CcSEcCtD
Escitalopram—Hypersensitivity—Paclitaxel—kidney cancer	5.15e-05	0.000112	CcSEcCtD
Escitalopram—Urinary tract disorder—Doxorubicin—kidney cancer	5.14e-05	0.000111	CcSEcCtD
Escitalopram—Oedema peripheral—Doxorubicin—kidney cancer	5.13e-05	0.000111	CcSEcCtD
Escitalopram—Connective tissue disorder—Doxorubicin—kidney cancer	5.12e-05	0.000111	CcSEcCtD
Escitalopram—Dyspnoea—Capecitabine—kidney cancer	5.12e-05	0.000111	CcSEcCtD
Escitalopram—Urethral disorder—Doxorubicin—kidney cancer	5.1e-05	0.000111	CcSEcCtD
Escitalopram—Dyspepsia—Capecitabine—kidney cancer	5.05e-05	0.000109	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—kidney cancer	5.02e-05	0.000109	CcSEcCtD
Escitalopram—Asthenia—Paclitaxel—kidney cancer	5.02e-05	0.000109	CcSEcCtD
Escitalopram—Decreased appetite—Capecitabine—kidney cancer	4.99e-05	0.000108	CcSEcCtD
Escitalopram—Nausea—Gemcitabine—kidney cancer	4.96e-05	0.000107	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Capecitabine—kidney cancer	4.96e-05	0.000107	CcSEcCtD
Escitalopram—Fatigue—Capecitabine—kidney cancer	4.95e-05	0.000107	CcSEcCtD
Escitalopram—Pruritus—Paclitaxel—kidney cancer	4.95e-05	0.000107	CcSEcCtD
Escitalopram—Erythema multiforme—Doxorubicin—kidney cancer	4.92e-05	0.000107	CcSEcCtD
Escitalopram—Pain—Capecitabine—kidney cancer	4.91e-05	0.000106	CcSEcCtD
Escitalopram—Constipation—Capecitabine—kidney cancer	4.91e-05	0.000106	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—kidney cancer	4.87e-05	0.000105	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—kidney cancer	4.86e-05	0.000105	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—kidney cancer	4.83e-05	0.000105	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—kidney cancer	4.83e-05	0.000105	CcSEcCtD
Escitalopram—Diarrhoea—Paclitaxel—kidney cancer	4.79e-05	0.000104	CcSEcCtD
Escitalopram—Feeling abnormal—Capecitabine—kidney cancer	4.73e-05	0.000102	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—kidney cancer	4.72e-05	0.000102	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—kidney cancer	4.7e-05	0.000102	CcSEcCtD
Escitalopram—Gastrointestinal pain—Capecitabine—kidney cancer	4.69e-05	0.000102	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—kidney cancer	4.69e-05	0.000102	CcSEcCtD
Escitalopram—Chills—Doxorubicin—kidney cancer	4.67e-05	0.000101	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—kidney cancer	4.65e-05	0.000101	CcSEcCtD
Escitalopram—Dizziness—Paclitaxel—kidney cancer	4.62e-05	0.0001	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—kidney cancer	4.6e-05	9.97e-05	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—kidney cancer	4.56e-05	9.88e-05	CcSEcCtD
Escitalopram—Urticaria—Capecitabine—kidney cancer	4.56e-05	9.87e-05	CcSEcCtD
Escitalopram—Body temperature increased—Capecitabine—kidney cancer	4.54e-05	9.83e-05	CcSEcCtD
Escitalopram—Abdominal pain—Capecitabine—kidney cancer	4.54e-05	9.83e-05	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—kidney cancer	4.53e-05	9.82e-05	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—kidney cancer	4.53e-05	9.82e-05	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—kidney cancer	4.47e-05	9.67e-05	CcSEcCtD
Escitalopram—Tension—Doxorubicin—kidney cancer	4.45e-05	9.63e-05	CcSEcCtD
Escitalopram—Vomiting—Paclitaxel—kidney cancer	4.45e-05	9.63e-05	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—kidney cancer	4.44e-05	9.61e-05	CcSEcCtD
Escitalopram—Rash—Paclitaxel—kidney cancer	4.41e-05	9.55e-05	CcSEcCtD
Escitalopram—Dermatitis—Paclitaxel—kidney cancer	4.41e-05	9.54e-05	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—kidney cancer	4.4e-05	9.53e-05	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—kidney cancer	4.38e-05	9.5e-05	CcSEcCtD
Escitalopram—Headache—Paclitaxel—kidney cancer	4.38e-05	9.49e-05	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—kidney cancer	4.36e-05	9.44e-05	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—kidney cancer	4.27e-05	9.25e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Capecitabine—kidney cancer	4.23e-05	9.16e-05	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—kidney cancer	4.21e-05	9.11e-05	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—kidney cancer	4.19e-05	9.07e-05	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—kidney cancer	4.17e-05	9.02e-05	CcSEcCtD
Escitalopram—Nausea—Paclitaxel—kidney cancer	4.15e-05	9e-05	CcSEcCtD
Escitalopram—Asthenia—Capecitabine—kidney cancer	4.12e-05	8.92e-05	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—kidney cancer	4.09e-05	8.85e-05	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—kidney cancer	4.07e-05	8.82e-05	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—kidney cancer	4.07e-05	8.8e-05	CcSEcCtD
Escitalopram—Pruritus—Capecitabine—kidney cancer	4.06e-05	8.79e-05	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—kidney cancer	4.06e-05	8.79e-05	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—kidney cancer	4.01e-05	8.68e-05	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—kidney cancer	3.98e-05	8.63e-05	CcSEcCtD
Escitalopram—Cough—Doxorubicin—kidney cancer	3.96e-05	8.57e-05	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—kidney cancer	3.93e-05	8.51e-05	CcSEcCtD
Escitalopram—Diarrhoea—Capecitabine—kidney cancer	3.93e-05	8.5e-05	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—kidney cancer	3.91e-05	8.48e-05	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—kidney cancer	3.86e-05	8.36e-05	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—kidney cancer	3.86e-05	8.36e-05	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—kidney cancer	3.86e-05	8.36e-05	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—kidney cancer	3.85e-05	8.33e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.83e-05	8.3e-05	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—kidney cancer	3.81e-05	8.26e-05	CcSEcCtD
Escitalopram—Dizziness—Capecitabine—kidney cancer	3.8e-05	8.22e-05	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—kidney cancer	3.77e-05	8.17e-05	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—kidney cancer	3.73e-05	8.08e-05	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—kidney cancer	3.7e-05	8.01e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—kidney cancer	3.7e-05	8.01e-05	CcSEcCtD
Escitalopram—Infection—Doxorubicin—kidney cancer	3.68e-05	7.96e-05	CcSEcCtD
Escitalopram—Vomiting—Capecitabine—kidney cancer	3.65e-05	7.9e-05	CcSEcCtD
Escitalopram—Shock—Doxorubicin—kidney cancer	3.64e-05	7.88e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—kidney cancer	3.63e-05	7.86e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—kidney cancer	3.62e-05	7.84e-05	CcSEcCtD
Escitalopram—Rash—Capecitabine—kidney cancer	3.62e-05	7.84e-05	CcSEcCtD
Escitalopram—Dermatitis—Capecitabine—kidney cancer	3.62e-05	7.83e-05	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—kidney cancer	3.61e-05	7.82e-05	CcSEcCtD
Escitalopram—Headache—Capecitabine—kidney cancer	3.6e-05	7.79e-05	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—kidney cancer	3.59e-05	7.78e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—kidney cancer	3.58e-05	7.75e-05	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—kidney cancer	3.53e-05	7.64e-05	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—kidney cancer	3.46e-05	7.49e-05	CcSEcCtD
Escitalopram—Nausea—Capecitabine—kidney cancer	3.41e-05	7.38e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.37e-05	7.3e-05	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—kidney cancer	3.35e-05	7.25e-05	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—kidney cancer	3.32e-05	7.19e-05	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—kidney cancer	3.3e-05	7.14e-05	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—kidney cancer	3.29e-05	7.12e-05	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—kidney cancer	3.26e-05	7.05e-05	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—kidney cancer	3.22e-05	6.96e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.19e-05	6.92e-05	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—kidney cancer	3.19e-05	6.91e-05	CcSEcCtD
Escitalopram—Pain—Doxorubicin—kidney cancer	3.16e-05	6.85e-05	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—kidney cancer	3.16e-05	6.85e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—kidney cancer	3.05e-05	6.6e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—kidney cancer	3.03e-05	6.55e-05	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—kidney cancer	2.94e-05	6.36e-05	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—kidney cancer	2.92e-05	6.33e-05	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—kidney cancer	2.92e-05	6.33e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—kidney cancer	2.73e-05	5.9e-05	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—kidney cancer	2.65e-05	5.75e-05	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—kidney cancer	2.62e-05	5.67e-05	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—kidney cancer	2.53e-05	5.48e-05	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—kidney cancer	2.45e-05	5.3e-05	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—kidney cancer	2.35e-05	5.09e-05	CcSEcCtD
Escitalopram—Rash—Doxorubicin—kidney cancer	2.33e-05	5.05e-05	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—kidney cancer	2.33e-05	5.05e-05	CcSEcCtD
Escitalopram—Headache—Doxorubicin—kidney cancer	2.32e-05	5.02e-05	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—kidney cancer	2.2e-05	4.76e-05	CcSEcCtD
Escitalopram—HTR2C—Signaling Pathways—FLT1—kidney cancer	1.38e-05	0.000358	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.34e-05	0.000349	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPAT—kidney cancer	1.34e-05	0.000349	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNA1—kidney cancer	1.33e-05	0.000347	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNA1—kidney cancer	1.33e-05	0.000346	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HSPB1—kidney cancer	1.32e-05	0.000345	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EIF4EBP1—kidney cancer	1.32e-05	0.000345	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CA9—kidney cancer	1.32e-05	0.000344	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HSPB1—kidney cancer	1.32e-05	0.000344	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EIF4EBP1—kidney cancer	1.32e-05	0.000344	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNA1—kidney cancer	1.31e-05	0.00034	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EIF4EBP1—kidney cancer	1.3e-05	0.000338	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HSPB1—kidney cancer	1.3e-05	0.000338	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—POMC—kidney cancer	1.3e-05	0.000338	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PAK1—kidney cancer	1.28e-05	0.000332	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JUNB—kidney cancer	1.28e-05	0.000332	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—FH—kidney cancer	1.25e-05	0.000324	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—APRT—kidney cancer	1.25e-05	0.000324	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ANXA1—kidney cancer	1.23e-05	0.00032	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PSMD7—kidney cancer	1.23e-05	0.00032	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TSC1—kidney cancer	1.23e-05	0.00032	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PSMD7—kidney cancer	1.23e-05	0.000319	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TSC1—kidney cancer	1.23e-05	0.000319	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ANXA1—kidney cancer	1.23e-05	0.000319	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CRABP1—kidney cancer	1.22e-05	0.000318	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TSC1—kidney cancer	1.21e-05	0.000314	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ANXA1—kidney cancer	1.21e-05	0.000314	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PSMD7—kidney cancer	1.21e-05	0.000314	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FLT1—kidney cancer	1.19e-05	0.00031	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FLT1—kidney cancer	1.19e-05	0.000309	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—POMC—kidney cancer	1.18e-05	0.000307	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GPC3—kidney cancer	1.17e-05	0.000305	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FLT1—kidney cancer	1.17e-05	0.000305	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CA2—kidney cancer	1.14e-05	0.000297	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ITPR2—kidney cancer	1.13e-05	0.000295	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—POMC—kidney cancer	1.12e-05	0.000293	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CRABP1—kidney cancer	1.12e-05	0.000292	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—POMC—kidney cancer	1.12e-05	0.000292	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALAD—kidney cancer	1.11e-05	0.000289	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PAK1—kidney cancer	1.11e-05	0.000288	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JUNB—kidney cancer	1.11e-05	0.000288	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—POMC—kidney cancer	1.1e-05	0.000287	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PAK1—kidney cancer	1.1e-05	0.000287	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JUNB—kidney cancer	1.1e-05	0.000287	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JUNB—kidney cancer	1.08e-05	0.000282	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PAK1—kidney cancer	1.08e-05	0.000282	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.08e-05	0.000282	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.06e-05	0.000276	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.05e-05	0.000272	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ITPR2—kidney cancer	1.04e-05	0.000272	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF2—kidney cancer	1.04e-05	0.000271	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN2B—kidney cancer	1.04e-05	0.00027	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTT1—kidney cancer	1.03e-05	0.000269	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ACHE—kidney cancer	1.03e-05	0.000269	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—POMC—kidney cancer	1.02e-05	0.000266	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—POMC—kidney cancer	1.02e-05	0.000265	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PGK1—kidney cancer	1.02e-05	0.000264	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.02e-05	0.000264	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF1R—kidney cancer	1.01e-05	0.000262	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—POMC—kidney cancer	1e-05	0.000261	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—LDHB—kidney cancer	9.96e-06	0.000259	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SCARB1—kidney cancer	9.8e-06	0.000255	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—RAF1—kidney cancer	9.71e-06	0.000253	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS1—kidney cancer	9.7e-06	0.000252	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—IL2—kidney cancer	9.59e-06	0.00025	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTT1—kidney cancer	9.52e-06	0.000248	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ACHE—kidney cancer	9.52e-06	0.000248	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PSMD7—kidney cancer	9.51e-06	0.000248	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF2—kidney cancer	9.04e-06	0.000235	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—BCHE—kidney cancer	9.02e-06	0.000235	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SCARB1—kidney cancer	9.01e-06	0.000235	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF2—kidney cancer	9.01e-06	0.000234	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN2B—kidney cancer	9e-06	0.000234	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	8.97e-06	0.000233	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS1—kidney cancer	8.92e-06	0.000232	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC5A5—kidney cancer	8.91e-06	0.000232	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF2—kidney cancer	8.87e-06	0.000231	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN2B—kidney cancer	8.83e-06	0.00023	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PSMD7—kidney cancer	8.75e-06	0.000228	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF1R—kidney cancer	8.74e-06	0.000227	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL2—kidney cancer	8.71e-06	0.000227	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF1R—kidney cancer	8.71e-06	0.000227	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CA9—kidney cancer	8.63e-06	0.000225	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC2A1—kidney cancer	8.6e-06	0.000224	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	8.57e-06	0.000223	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—RAF1—kidney cancer	8.42e-06	0.000219	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—RAF1—kidney cancer	8.39e-06	0.000218	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.34e-06	0.000217	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—IL2—kidney cancer	8.31e-06	0.000216	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HIF1A—kidney cancer	8.3e-06	0.000216	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—BCHE—kidney cancer	8.29e-06	0.000216	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—IL2—kidney cancer	8.29e-06	0.000216	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TSC2—kidney cancer	8.28e-06	0.000216	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	8.26e-06	0.000215	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC5A5—kidney cancer	8.19e-06	0.000213	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	8.16e-06	0.000212	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KDR—kidney cancer	7.94e-06	0.000207	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC2A1—kidney cancer	7.91e-06	0.000206	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL2—kidney cancer	7.55e-06	0.000197	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL2—kidney cancer	7.52e-06	0.000196	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL2—kidney cancer	7.41e-06	0.000193	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CRABP1—kidney cancer	7.34e-06	0.000191	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KIT—kidney cancer	7.31e-06	0.00019	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—APC—kidney cancer	7.31e-06	0.00019	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.28e-06	0.000189	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HIF1A—kidney cancer	7.19e-06	0.000187	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TSC2—kidney cancer	7.17e-06	0.000187	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTP1—kidney cancer	7.17e-06	0.000187	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HIF1A—kidney cancer	7.17e-06	0.000187	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TSC2—kidney cancer	7.15e-06	0.000186	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	7.06e-06	0.000184	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TSC2—kidney cancer	7.04e-06	0.000183	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	7e-06	0.000182	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—POMC—kidney cancer	6.96e-06	0.000181	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KDR—kidney cancer	6.88e-06	0.000179	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—BRAF—kidney cancer	6.87e-06	0.000179	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KDR—kidney cancer	6.86e-06	0.000178	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ITPR2—kidney cancer	6.82e-06	0.000178	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ABCB1—kidney cancer	6.79e-06	0.000177	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KDR—kidney cancer	6.75e-06	0.000176	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	6.66e-06	0.000173	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTP1—kidney cancer	6.6e-06	0.000172	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTM1—kidney cancer	6.59e-06	0.000172	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	6.37e-06	0.000166	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KIT—kidney cancer	6.34e-06	0.000165	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—APC—kidney cancer	6.34e-06	0.000165	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—APC—kidney cancer	6.32e-06	0.000164	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KIT—kidney cancer	6.32e-06	0.000164	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—kidney cancer	6.29e-06	0.000164	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP1A1—kidney cancer	6.25e-06	0.000163	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—kidney cancer	6.25e-06	0.000163	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—kidney cancer	6.22e-06	0.000162	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ACHE—kidney cancer	6.22e-06	0.000162	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APC—kidney cancer	6.22e-06	0.000162	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KIT—kidney cancer	6.22e-06	0.000162	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK3—kidney cancer	6.07e-06	0.000158	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTM1—kidney cancer	6.06e-06	0.000158	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	6.05e-06	0.000157	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—POMC—kidney cancer	6.03e-06	0.000157	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—POMC—kidney cancer	6.01e-06	0.000157	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BRAF—kidney cancer	5.96e-06	0.000155	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	5.95e-06	0.000155	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BRAF—kidney cancer	5.94e-06	0.000155	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—POMC—kidney cancer	5.92e-06	0.000154	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SCARB1—kidney cancer	5.89e-06	0.000153	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BRAF—kidney cancer	5.84e-06	0.000152	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS1—kidney cancer	5.83e-06	0.000152	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	5.78e-06	0.000151	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK1—kidney cancer	5.77e-06	0.00015	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	5.76e-06	0.00015	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP1A1—kidney cancer	5.75e-06	0.00015	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RAF1—kidney cancer	5.74e-06	0.000149	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PSMD7—kidney cancer	5.72e-06	0.000149	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RELA—kidney cancer	5.71e-06	0.000149	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—kidney cancer	5.68e-06	0.000148	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	5.67e-06	0.000147	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MTOR—kidney cancer	5.6e-06	0.000146	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	5.52e-06	0.000144	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	5.5e-06	0.000143	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—kidney cancer	5.45e-06	0.000142	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—kidney cancer	5.44e-06	0.000142	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—BCHE—kidney cancer	5.42e-06	0.000141	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	5.41e-06	0.000141	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC5A5—kidney cancer	5.35e-06	0.000139	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	5.35e-06	0.000139	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	5.26e-06	0.000137	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC2A1—kidney cancer	5.17e-06	0.000135	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—kidney cancer	5.15e-06	0.000134	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.13e-06	0.000134	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—kidney cancer	5.02e-06	0.000131	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	5.01e-06	0.00013	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JUN—kidney cancer	5.01e-06	0.00013	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.99e-06	0.00013	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RAF1—kidney cancer	4.97e-06	0.000129	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	4.97e-06	0.000129	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RAF1—kidney cancer	4.96e-06	0.000129	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RELA—kidney cancer	4.95e-06	0.000129	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RELA—kidney cancer	4.93e-06	0.000128	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—kidney cancer	4.92e-06	0.000128	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	4.92e-06	0.000128	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—kidney cancer	4.9e-06	0.000128	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RAF1—kidney cancer	4.88e-06	0.000127	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RELA—kidney cancer	4.86e-06	0.000126	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MTOR—kidney cancer	4.86e-06	0.000126	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—kidney cancer	4.84e-06	0.000126	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MTOR—kidney cancer	4.84e-06	0.000126	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	4.83e-06	0.000126	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MTOR—kidney cancer	4.76e-06	0.000124	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—POMC—kidney cancer	4.66e-06	0.000121	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1B—kidney cancer	4.56e-06	0.000119	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	4.54e-06	0.000118	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	4.47e-06	0.000116	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—kidney cancer	4.46e-06	0.000116	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—kidney cancer	4.44e-06	0.000116	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—kidney cancer	4.38e-06	0.000114	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—kidney cancer	4.37e-06	0.000114	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—kidney cancer	4.35e-06	0.000113	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JUN—kidney cancer	4.34e-06	0.000113	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—kidney cancer	4.33e-06	0.000113	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JUN—kidney cancer	4.32e-06	0.000113	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—kidney cancer	4.31e-06	0.000112	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNB1—kidney cancer	4.3e-06	0.000112	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	4.29e-06	0.000112	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—POMC—kidney cancer	4.29e-06	0.000112	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—kidney cancer	4.27e-06	0.000111	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JUN—kidney cancer	4.26e-06	0.000111	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	4.22e-06	0.00011	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—kidney cancer	4.2e-06	0.000109	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—kidney cancer	4.18e-06	0.000109	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK3—kidney cancer	4.14e-06	0.000108	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—kidney cancer	4.12e-06	0.000107	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—kidney cancer	4.08e-06	0.000106	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—kidney cancer	4.02e-06	0.000105	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTM1—kidney cancer	3.96e-06	0.000103	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK1—kidney cancer	3.94e-06	0.000102	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—kidney cancer	3.79e-06	9.87e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—kidney cancer	3.78e-06	9.83e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.76e-06	9.78e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	3.72e-06	9.68e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—kidney cancer	3.72e-06	9.68e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—kidney cancer	3.72e-06	9.67e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK3—kidney cancer	3.58e-06	9.33e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK3—kidney cancer	3.57e-06	9.3e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	3.52e-06	9.16e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—kidney cancer	3.49e-06	9.08e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—kidney cancer	3.48e-06	9.05e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—kidney cancer	3.42e-06	8.91e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—kidney cancer	3.42e-06	8.9e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	3.42e-06	8.89e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK1—kidney cancer	3.41e-06	8.88e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK1—kidney cancer	3.4e-06	8.85e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	3.35e-06	8.71e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—kidney cancer	3.3e-06	8.6e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—kidney cancer	3.24e-06	8.44e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—kidney cancer	3.22e-06	8.39e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—kidney cancer	3.21e-06	8.36e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—kidney cancer	3.16e-06	8.23e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—kidney cancer	2.98e-06	7.76e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—kidney cancer	2.96e-06	7.71e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.95e-06	7.68e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	2.9e-06	7.56e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—kidney cancer	2.86e-06	7.45e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—kidney cancer	2.85e-06	7.43e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—kidney cancer	2.81e-06	7.31e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—POMC—kidney cancer	2.8e-06	7.29e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.29e-06	5.95e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—kidney cancer	2.23e-06	5.82e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.1e-06	5.47e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—kidney cancer	1.95e-06	5.07e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.37e-06	3.58e-05	CbGpPWpGaD
